Cortagen
Also known as: Cortagen peptide, AEDP, Ala-Glu-Asp-Pro
4 notable studies · 4 references
TLDR
Cortagen is a synthetic four-amino-acid peptide bioregulator derived from research on cerebral-cortex peptide preparations, with preclinical evidence for effects on tissue growth and gene expression but a sparse and highly concentrated evidence base that does not currently establish cognitive, neuroprotective, or anti-aging efficacy in humans.
Research Supports
- Studied for gene-expression changes in animal tissue following exposure
- Investigated for relevance to brain aging and age-related cellular processes
- Studied in nervous-system injury and age-related dysfunction models (neuroprotection)
- Referenced in older human reports on peripheral nerve recovery, not independently verified
- Studied for tissue-specific effects in organotypic culture and immune-cell signaling
Observations Reported in Research
- Microarray study found altered expression across multiple genes in mouse cardiac tissue (2004)
- Stimulated growth of rat cerebral-cortex explants in organotypic culture (Khavinson, 2001)
- Altered IL-2 mRNA synthesis in mouse splenocytes, less pronounced than Vilon or Epitalon (Kazakova et al., 2002)
- Showed relatively little activity on thymocyte endpoints compared with Vilon (Khavinson et al., 2002)
- Human evidence is limited to historical reports rather than independently replicated trials
These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.
At a Glance
Classification: Synthetic tetrapeptide; short peptide bioregulator; experimental neuroregulatory peptide
Cortagen is a synthetic four-amino-acid peptide: Ala-Glu-Asp-Pro, or AEDP. It belongs to the family of short peptide “bioregulators” developed largely by researchers associated with the St. Petersburg Institute of Bioregulation and Gerontology. Cortagen was developed following analysis of Cortexin, a complex peptide preparation derived from cerebral cortex. Research has investigated Cortagen in relation to brain aging, neuronal gene expression, neuroprotection, oxidative stress, peripheral nerve injury, neuroendocrine regulation, and aging-related molecular changes. But the evidence situation is radically different from Tβ4: Cortagen's literature is small, geographically and investigator concentrated, and predominantly preclinical. Claims of broad cognitive enhancement, brain rejuvenation or established neuroprotection in humans go substantially beyond the evidence currently available in mainstream indexed literature.
What Is Cortagen?
Cortagen was produced through directed peptide synthesis following amino-acid analysis of the natural peptide preparation Cortexin. Its sequence is Ala-Glu-Asp-Pro. Researchers classify it among very short peptide bioregulators intended to reproduce tissue-associated regulatory signals. A published microarray paper explicitly describes Cortagen as a synthetic tetrapeptide derived through analysis of the natural cerebral-cortex preparation Cortexin. This gives us another important Aminodex distinction: Cortagen ≠ Cortexin. Cortagen is a defined four-amino-acid molecule: AEDP. Cortexin is a complex peptide preparation derived from animal cerebral cortex. Evidence involving Cortexin should not automatically be assigned to Cortagen.
What Are Researchers Studying?
Gene expression
A recurring theme in the short-peptide-bioregulator literature is regulation of gene expression. A microarray experiment examined mouse cardiac tissue after Cortagen exposure and reported changes in expression of multiple genes. Other work from this research tradition proposes interactions between short peptides, chromatin and gene regulatory processes. However, mechanistic claims should be kept conservative. Changes in gene expression after peptide exposure do not by themselves establish a specific therapeutic effect.
Brain aging
Cortagen was developed specifically around the concept of a brain cortex-associated peptide bioregulator. Experimental work has investigated whether AEDP influences cellular processes altered during aging. But there is currently no robust modern clinical evidence demonstrating that Cortagen: - reverses cognitive aging - prevents dementia - improves healthy human memory - extends lifespan - “rejuvenates” the human brain. Those are much stronger claims than the available evidence supports.
Neuroprotection
Experimental literature has examined Cortagen in models involving nervous-system injury and age-related dysfunction. Some publications describe effects on neuronal survival, oxidative processes and recovery-related biology. The mechanistic evidence remains considerably less developed than for established neurotrophic systems such as BDNF or NGF.
Peripheral nerve recovery
The Cortagen literature includes claims of therapeutic effects during post-traumatic recovery of peripheral nerve tissue. Interestingly, the 2004 gene-expression paper itself states that prior human work had reported a pronounced therapeutic effect during structural and functional post-traumatic peripheral-nerve recovery. However, this is exactly where Aminodex needs to be strict: a statement about prior human findings inside another paper is not equivalent to having a high-quality randomized human trial in hand. Until the original clinical reports can be independently located and assessed, human efficacy should be classified as uncertain/poorly documented rather than established.
Tissue-specific peptide signaling
Researchers associated with the peptide-bioregulator field propose that different short peptides preferentially influence different tissues. In an organotypic culture experiment: - Cortagen stimulated growth of rat brain-cortex explants - Epitalon stimulated subcortical structures - Livagen stimulated liver tissue - Vilon stimulated thymic tissue. That's intriguing evidence for differential activity. But it remains an ex-vivo rat tissue experiment, not proof of highly selective targeting inside humans.
Immune signaling
Cortagen has also appeared in experiments examining immune-cell signaling. One mouse splenocyte study found that Cortagen could influence IL-2 mRNA expression, although its effect was less pronounced than Vilon or Epitalon under the tested conditions. Another mouse thymocyte experiment found relatively little effect from Cortagen compared with the other short peptides tested. This is actually valuable because it shows that the literature isn't uniformly positive.
How Does It Work?
The mechanism remains uncertain. Proposed biology includes effects on gene expression, chromatin-associated regulation, cellular differentiation, oxidative-stress responses, and tissue-specific signaling. A simplified vendor-style explanation such as “Cortagen → enters brain → switches on youthful genes” would substantially overstate what has been demonstrated. The defensible version is: Experimental studies suggest that Cortagen can alter cellular and gene-expression responses in several model systems, but its primary molecular target and clinically relevant mechanism have not been firmly established.
What Does the Research Show?
Human research
This is weak. Historical publications from the Cortagen research group reference human therapeutic experience, including peripheral nerve recovery. But compared with compounds such as Semaglutide, HCG, Afamelanotide, or even Thymosin Beta-4, the accessible peer-reviewed human evidence base is extremely limited. For Aminodex purposes this should be classified as Human evidence: LIMITED / INSUFFICIENTLY DOCUMENTED rather than “none,” because historical clinical claims do exist. But we should not elevate secondary references into high-quality clinical evidence.
Animal research
Most of the research base is here. Experimental studies involve rodents, organotypic tissue cultures, aging models, gene-expression experiments, and immune-cell experiments. The evidence supports biological activity. It does not yet establish a human therapeutic effect.
In-vitro research
This is probably the strongest direct evidence category. Experiments have reported effects involving tissue explant growth, gene expression, IL-2 transcription, and cellular signaling. For example, Cortagen stimulated rat cerebral-cortex explant growth in organotypic culture.
Notable Studies
Elucidation of the Effect of Brain Cortex Tetrapeptide Cortagen on Gene Expression in Mouse Heart by Microarray
animalResearchers administered Cortagen and used microarray analysis to investigate changes in cardiac gene expression. The experiment identified altered expression across multiple transcripts and was intended to explore molecular pathways potentially underlying previously observed biological effects of the peptide.
Limitations: Mouse experiment examining gene-expression changes rather than clinical neurological outcomes. Gene-expression changes do not establish therapeutic benefit.
View publication →Tissue-Specific Effects of Peptides
in-vitroSynthetic short peptides were applied to rat tissue explants. Cortagen preferentially stimulated growth of brain-cortex explants, while other peptide bioregulators showed different tissue-associated effects.
Limitations: Ex-vivo rat tissue culture, not an intact-animal or human clinical study. It does not establish that Cortagen selectively targets the human cerebral cortex after administration.
View publication →In Vitro Effect of Short Peptides on Expression of Interleukin-2 Gene in Splenocytes
animalResearchers exposed mouse splenocytes to Vilon, Epitalon and Cortagen. Cortagen altered IL-2 mRNA synthesis, although the effect was less pronounced than that produced by Vilon and Epitalon.
Limitations: Isolated mouse immune cells rather than neurological tissue or human participants. Relevance to proposed cognitive/neuroprotective effects is uncertain.
View publication →Effects of Short Peptides on Thymocyte Blast Transformation and Signal Transduction Along the Sphingomyelin Pathway
animalResearchers compared Vilon, Epitalon and Cortagen in mouse thymocytes. Cortagen showed relatively little activity in several measured immune-cell endpoints compared with Vilon.
Limitations: Mouse immune-cell experiment with uncertain relevance to Cortagen's proposed neurological applications.
View publication →What We Still Don't Know
A lot: human pharmacokinetics; oral bioavailability; blood-brain-barrier exposure; effective human exposure; primary molecular target; whether purported tissue specificity occurs in humans; whether Cortagen improves human cognition; whether it improves recovery after nerve injury; whether it affects dementia; whether it modifies brain aging; long-term human safety; drug interactions; reproductive safety; whether effects replicate independently of the original research network; whether research-market Cortagen accurately matches AEDP used experimentally.
Related Compounds
Recent publications
Latest titles from PubMed, not reviewed by Aminodex. Not an endorsement. See all on PubMed ↗
Take the Cortagen research with you.
Get the Aminodex Cortagen Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.
One-time email. We do not add you to any mailing list.
Sources & References
- citation: Elucidation of the Effect of Brain Cortex Tetrapeptide Cortagen on Gene Expression in Mouse Heart by Microarray. 2004.
- citation: Khavinson VK. Tissue-Specific Effects of Peptides. 2001.
- citation: Kazakova TB, et al. In Vitro Effect of Short Peptides on Expression of Interleukin-2 Gene in Splenocytes. 2002.
- citation: Khavinson VK, et al. Effects of Short Peptides on Thymocyte Blast Transformation and Signal Transduction Along the Sphingomyelin Pathway. 2002.
Supplier Listings
Disclosure: The owner of Aminodex operates the supplier(s) marked below. These listings are promotion for businesses we own, not independent recommendations. Read our disclosures.